載入中
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
前收盤價
US$95.01
+US$2.25 · +2.43%
盤前
US$95.02
+US$0.01 · +0.01%
10月12日 上午7:45 ET
盤中時間採用ET。市場資料可能有所延遲。
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
日內區間
目前US$95.01
52週區間
目前US$95.01
盤中時間採用ET。市場資料可能有所延遲。
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
日內區間
目前US$95.01
52週區間
目前US$95.01
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 130萬 USD | 20萬 USD | 180萬 USD | 219.2萬 USD | 712.5萬 USD |
| 銷貨成本 | 248.3萬 USD | 228.5萬 USD | 119.1萬 USD | 1.1億 USD | 268.8萬 USD |
| 毛利 | −118.3萬 USD | −208.5萬 USD | 60.9萬 USD | −1.08億 USD | 443.7萬 USD |
| 研究與開發 | 1.13億 USD | 2.04億 USD | 1.91億 USD | 1.1億 USD | 7144萬 USD |
| 銷售、一般及管理費用 | 2329.7萬 USD | 1.28億 USD | 2938.1萬 USD | 2112.3萬 USD | 966.7萬 USD |
| 營業費用 | 1.34億 USD | 3.29億 USD | 2.2億 USD | 2112.2萬 USD | 8110.7萬 USD |
| 利息收入 | 754.9萬 USD | 1094萬 USD | 1191.7萬 USD | — | — |
| 利息支出 | 1219.6萬 USD | 1349.1萬 USD | 3184萬 USD | 1610.7萬 USD | 521.6萬 USD |
| 折舊和攤銷 | 248.3萬 USD | 228.5萬 USD | 119.1萬 USD | 122.5萬 USD | 119.5萬 USD |
| 營業利益 | −1.35億 USD | −3.31億 USD | −2.19億 USD | −1.29億 USD | −7667萬 USD |
| 淨利 | −1.4億 USD | 16.88億 USD | −2.41億 USD | −1.45億 USD | −8176.8萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$285
上漲空間 199.97%| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2024年5月30日 | US$0.85Irregular | 2024年5月30日 | 2024年6月20日 |
除息 2024年5月30日
US$0.85
Irregular
2024年5月30日登記 · 支付日 2024年6月20日
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI4683.35萬0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI3053.56萬0.31%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM2337.77萬0.03%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF1420.18萬0.01%954億 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB790.06萬0.08%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO692.16萬0.04%180億 USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO664.84萬0.05%139.17億 USD0.24%US$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA488.22萬0.02%218.24億 USD0.03%US$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
